FundersClub focuses on Seed and early stage investments. Investments include Coinbase, Instacart, Flexport, Le Tote, Teespring, Memebox, GitLab. FundersClub is the world's first online venture capital platform. Backed by Y Combinator, First Round Capital, Spark Capital, Intel Capital, Draper, Andreessen Horowitz, Felicis Ventures, and more; FundersClub Inc. was founded in 2012 and is based in the United States.

FundersClub

Kleiner Perkins is a venture capital firm specializing in investing in early-stage, growth, and incubation companies. The firm continues that legacy, investing in founders with bold ideas that span industries and continents, partnering with them from inception to IPO and beyond to maximize the potential of their ideas. They also focus on early computer firms using their devices and programming and service companies. It also invests in the digital, life sciences, and healthcare industries.

Kleiner Perkins

Founders Fund is a venture capital firm that invests at every stage in companies building revolutionary technologies. It has been investors, founders, and early employees of prominent technology companies. It has historically invested in a wide variety of sectors, including aerospace, artificial intelligence, advanced computing, energy, health, and consumer Internet.

Founders Fund

8VC seeks to enable industry transformation. In a wave of creative destruction, they believe emerging platforms will replace the decades-old technology infrastructure behind many industries, promoting greater innovation and prosperity.

Quiet Capital is a technology investment firm.

Quiet Capital

Delphi is dedicated to supporting the next generation of World-Positive founders with support, advice, and capital. Delphi invests in early-stage and late-stage companies and teams that hold promise to transform old-line industries with new, sustainable solutions.

Delphi VC

Left Lane Capital is a venture capital and seed-growth equity firm that invests in high-growth internet and consumer technology businesses that are fundamental to the human condition and spirit – where customers maintain a long-term relationship with the product, platform, or service.

Left Lane Capital

Four Acres is a pre-seed and seed stage venture capital fund focused on software-first technology companies with a competitive moat. It seeks entrepreneurs with a technical background, business acumen, laser-like focus, and unrivaled hustle. It offers post-investment support and services that address the most pressing needs of early-stage founders, giving them the tools and relationships they need to scale their businesses.

Four Acres Capital

Apply to join the syndicate at: https://angel.co/laborcapital/syndicate

Labor Capital

Mindbloom

Mindbloom is a mental health and wellbeing brand helping people achieve personal and clinical breakthroughs with at-home, clinician-prescribed psychedelic therapies. The company provides science-backed medicine designed by leading psychiatrists and facilitated by friendly, expert guides.

Mindbloom operates as a mental health and wellbeing company delivering medically supervised psychedelic therapies. The company opened its first psychedelic clinic to offer ketamine therapy in March 2020. Following the outbreak of Covid-19, it started offering virtually administered therapy sessions. The company offers ketamine treatment in the form of sublingual tablets that dissolve under the tongue, combined with virtual support from clinicians and guides. Each client receives a "Bloombox" containing items needed for treatment sessions, including an eye mask, blood pressure monitor, and journal. The platform provides therapeutic content, meditation guidance, and integration resources through its mobile app.

Promising research and receding stigma are giving investors cannabis-boom flashbacks.

Psychedelic Medicine

Mindbloom and Happier Break New Ground with the Ultimate Fusion of Ketamine Therapy and Mindfulness

Ten Percent Happier

To strengthen Mindbloom's foothold in the psychedelic therapy market and broaden its reach by integrating mindfulness practices, offering a more holistic approach to mental health care.

Companies operating clinics and treatment centers to deliver psychedelic therapies.

A new industry proving that digital connectivity and mental health can co-exist.

Digital Wellness

Apps that provide relaxation, stress reduction and non-therapeutic mental health support via meditation-related techniques.

Mindbloom operates as a mental health and wellbeing company delivering medically supervised psychedelic therapies. The company opened its first psychedelic clinic to offer ketamine therapy in March 2020. Following the outbreak of Covid-19, it started offering virtually administered therapy sessions. The company offers ketamine treatment in the form of sublingual tablets that dissolve under the tongue, combined with virtual support from clinicians and guides. Each client receives a "Bloombox" containing items needed for treatment sessions, including an eye mask, blood pressure monitor, and journal. The platform provides therapeutic content, meditation guidance, and integration resources through its mobile app.Further in&nbsp;<a href="https://sp-edge.com/updates/30559">June 2024</a>, the company launched a ketamine therapy program to treat individuals recovering from post-traumatic stress disorder. Mindbloom claims its key advantage over competitors is that it charges 70% less than other ketamine infusion clinics. It charges USD 196 per session (for new clients), which it claims is three times less than the average price charged at a ketamine infusion clinic.Key customers and partnershipsThe company operates a B2C business model, and as of October 2024, Mindbloom has facilitated over 500,000 ketamine therapy sessions.&nbsp;In&nbsp;<a href="https://sp-edge.com/updates/36081">November 2024</a>, the company partnered with meditation app Happier to launch 'Continuous Transformation,' combining ketamine therapy with mindfulness practices.

<div>
 
 Canadian biotech firm Core One Labs maintains three primary business operations: 1) developing novel delivery systems for psychedelic medicines, 2) psilocybin manufacturing, and 3) medical clinics to provide psychedelic-assisted psychotherapy. The company has developed proprietary technology with infused strips that dissolve immediately when placed in the patient&rsquo;s mouth to deliver molecules with a higher level of bioavailability. The company plans to advance this technology to incorporate psychedelic molecules, particularly psilocybin.&nbsp;
 
 
 Core One Labs also claims it has discovered a patentable method of producing high-quality psilocybin, which it may license to pharmaceutical companies. Additionally, the company has two psychedelic clinics in Vancouver that currently support clinical trials and maintain a database of more than 275,000 patients. The company acquired Vocan Biotechnologies and Akome Biotech in May 2021 for undisclosed amounts. Akome is developing a patent-pending psychedelic drug formulation for the treatment of Alzheimer&rsquo;s Disease.&nbsp;
 
 
 Core One Labs is listed on the Canadian Securities Exchange (CSE) and OTC markets.
 
 
</div>

Core One Labs

<div>
 
 Vancouver-based Lobe Sciences (formerly GreenStar Biosciences) is a biotechnology company developing psychedelic medicines (microdose applications) and medical devices for efficient drug delivery. The company&rsquo;s main focus is the treatment of mild traumatic brain injury and post-traumatic stress disorder (PTSD). It is also conducting early studies on psilocybin combined with N-acetylcysteine (NAC), and MDMA combined with NAC as a treatment. Lobe is also developing a patent pending nasal mist transducer device for the delivery of medicines directly to the brain&rsquo;s olfactory bulb.&nbsp;
 
 
 In June 2020, Lobe acquired Eleusian Biosciences, a company focused on the development of psychedelic medicine which expanded its intellectual property portfolio with three US patent applications for psychedelic therapeutics. Lobe is also collaborating with the University of Miami&rsquo;s Miller School of Medicine to conduct preclinical studies. After its restructuring and name change, the company started trading on the Canadian Securities Exchange (CSE) in November 2020.
 
 
 
</div>

Lobe Sciences

<div>
 
 Cybin is a psychedelic biotechnology company developing treatments for psychiatric and neurological conditions. Through its Serenity Life Science division, Cybin conducted Phase II of clinical trials on using psilocybin to treat major depressive disorder. Additionally, the company's Nature's Journey division focuses on creating non-psychedelic medicinal and nutraceutical mental health products.
 
 
 Cybin is actively building a patent portfolio, including chemically-synthesized compounds, delivery mechanisms, protocols, and new drug formulations. It has also filed an International Patent Application through the Patent Cooperation Treaty, potentially covering 153 countries.&nbsp;
 
 
 In July 2023, the company announced 
 <a href="https://sp-edge.com/updates/20076">
 EMBARKCT, 
 </a>
 a streamlined version of its EMBARK training program for pivotal studies of lead candidates, CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, respectively. In 
 <a href="https://sp-edge.com/updates/27577">
 March 2024
 </a>
 , the company received a breakthrough designation from the FDA for CYB003, and expects to initiate Phase III clinical trials for the program by mid-2024.
 
 
 Cybin implements an M&amp;A strategy to grow in the psychedelic industry. It did a reverse takeover of Charmin in June 2020, raising CAD 45 million (USD 35.5 million) for clinical studies. It acquired Adelia Therapeutics in December 2020, adding novel treatments and patent applications. Also in 
 <a href="https://sp-edge.com/updates/21335">
 August 2023 
 </a>
 it acquired 
 <a href="https://sp-edge.com/companies/470858">
 Small Pharma 
 </a>
 in an all-share transaction to strengthen its psychedelic portfolio.&nbsp;
 
 
 Founded in 2019, Cybin is listed on the NEO exchange under the ticker symbol &ldquo;CYBN&rdquo; and was uplisted to the NYSE American Stock Exchange in July 2021 under the same symbol. For FY2023, the company reported a decrease in net loss by 29.7% YoY to CAD 47.5 million (USD 35 million).&nbsp;
 Further in 
 <a href="https://sp-edge.com/updates/33849">
 September 2024
 </a>
 , it completed a 38-to-1 share consolidation of its common stock which reduced the number of outstanding common shares to ~20 million. 
 
 
 Key customers and partnerships&nbsp;
 
 
 In July 2020, Cybin expanded its operations and research activities in the European region via research partnerships and transferred its intellectual property assets to its fully-owned Irish subsidiary (formed in May 2021). In July 2023, the company partnered with 
 <a href="https://sp-edge.com/updates/20455">
 Worldwide Clinical Trials
 </a>
 to develop new psychedelic-based treatment options for mental health conditions, including major depressive disorder. Further, in September 2023, the company partnered with 
 <a href="https://sp-edge.com/updates/22180">
 Fluence
 </a>
 to support Cybin's EMBARK facilitator training program.
 
</div>

Cybin

<div>
 
 Canadian cannabinoid-based therapeutics company BioNxt Solutions
 (formerly Xphyto Therapeutics) announced in November 2020 that it has expanded its drug development program to incorporate a number of psychedelic compounds. This includes substances such as psilocybin, mescaline, LSD, MDMA, and DMT. Xphyto&rsquo;s initial focus is on developing standardized drug formulations with efficient delivery mechanisms for therapeutic use.
 
</div>

BioNxt Solutions

<div>
 
 New York-based Gilgamesh Pharmaceuticals is a biotechnology company developing psychedelic-inspired medicines for neuropsychiatric conditions such as depression, anxiety, addiction, and cognitive deficits. The company has three research programs in its pipeline: 1) Serotonergic Micro-Dose&ndash;a non psychedelic therapeutic treatment for attention deficit hyperactivity disorder (ADHD) and mood/anxiety disorders, 2) Arylcyclohexylamine&ndash;an improved molecule of ketamine for treatment-resistant depression and opiate use disorder, and 3) Novel Ibogaine Analogue&ndash;for the treatment of substance use disorders.&nbsp;
 
 
 Gilgamesh is one of the few psychedelic companies launched by the startup accelerator Y Combinator, and as such enjoys the accelerator&rsquo;s world-famous business expertise and network.
 
 
 Key customers and partnerships
 
 
 In 
 <a href="https://sp-edge.com/updates/29382">
 May 2024
 </a>
 , the company partnered with AbbVie to leverage AbbVie's psychiatric expertise and Gilgamesh's research platform to create novel &quot;neuroplastogens.&quot; 
 
 
 Funding and Financials
 
 
 In 
 <a href="https://sp-edge.com/updates/27575">
 March 2024
 </a>
 , the company received a grant of&nbsp; USD 14 million from the National Institute on Drug Abuse to develop the GM-3009 compound. Prior to this, it raised USD 39 million in a 
 <a href="https://sp-edge.com/updates/15359">
 Series B 
 </a>
 funding round led by Prime Movers Lab in December 2022. 
 
</div>

Gilgamesh Pharmaceuticals

Companies conducting research on psychedelic compounds and developing novel therapeutics.

Companies operating digital platforms to deliver psychedelic therapies including psychedelic integration, virtual experiences, and mental coaching and tracking. AI drug discovery companies specializing in psychedelic therapeutics are also included.

Companies supplying psychedelic compounds through cultivation, chemical synthesis and biosynthesis for medical research and drug development.

Companies building a patent portfolio of novel analogs and derivatives of first-generation psychedelics and new drug delivery mechanisms. 

ANALYST_QUICK_TAKE

PROMINENT_CATEGORY

<div>
 
 Mindbloom, a company based in New York, has entered into a partnership with the meditation app Happier. The partnership aims at launching "Continuous Transformation," a novel approach that merges ketamine therapy and mindfulness practices. 
 This collaboration will provide Mindbloom's clients with free access to over 500 guided meditations found on Happier, with these meditations being taught by more than 60 teachers. In return, users of Happier will receive discounts on Mindbloom's programs. These programs include 12 different paths aimed at tackling various mental health issues. Further, in the upcoming year, phase two of this partnership will be initiated. Named as "Meditation for Mindbloom, Powered by Happier," this phase will facilitate the integration of Happier's meditations into the Mindbloom app itself.
 
</div> Analyst QuickTake: 
 This partnership strengthens Mindbloom's foothold in the psychedelic therapy market while broadening its reach beyond the 500,000 clients it has already served. By integrating mindfulness practices, Mindbloom is poised to offer a more holistic approach to mental health care.

Mindbloom

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless